ReviewMolecular biology reports2025
Exploiting allosteric modulation: a new frontier for precision medicine.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine aims to revolutionize healthcare by tailoring treatments to the unique genetic, molecular, and environmental profiles of individuals. Among the innovative approaches in this field, allosteric modulation has emerged as a powerful strategy for therapeutic intervention. Allosteric modulators regulate protein activity by binding to sites distinct from the active site, offering enhanced specificity, versatility, and control over biological processes. This review explores the integration of allosteric modulation with precision medicine, highlighting its potential to address unmet medical needs in complex diseases such as cancer, neurodegenerative disorders, and metabolic conditions. The study utilized databases like PubMed, Scopus, and Web of Science to conduct a thorough search of peer-reviewed articles, reviews, and case studies published between 2012 and 2024. Allosteric modulators, driven by advancements in structural biology, artificial intelligence, and high-throughput screening, offer unique advantages in targeting undruggable proteins and overcoming drug resistance in personalized treatment strategies. The article discusses challenges in allosteric drug development, including off-target effects and clinical translation, and provides a framework for overcoming these barriers. This review highlights allosteric modulation's potential to revolutionise therapeutic strategies by enabling highly targeted, effective, and individualised treatments in next-generation healthcare.
Indexed as
Identifiers
40465033What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.